Investor Relations

Japanese

Japanese

Sep. 30, 2020 (PDF/98KB)R&D

Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep. 23, 2020 (PDF/98KB)Corporate

Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
Sep. 18, 2020 (PDF/542KB)Others

Sumitomo Dainippon Pharma and KDDI Announce Start of Initiatives to Create New Platform for Communication between MRs and HealthCare Professionals Using XR
Sep. 17, 2020 (PDF/80KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Executive Officer
Sep. 04, 2020 (PDF/104KB)Finances

Sumitomo Dainippon Pharma Determines Issuance Conditions for Publicly Offered Hybrid Bonds (Subordinated Bonds)

Sep. 30, 2020 (PDF/98KB)R&D

Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep. 23, 2020 (PDF/98KB)Corporate

Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
Sep. 18, 2020 (PDF/542KB)Others

Sumitomo Dainippon Pharma and KDDI Announce Start of Initiatives to Create New Platform for Communication between MRs and HealthCare Professionals Using XR
Sep. 17, 2020 (PDF/80KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Executive Officer
Sep. 04, 2020 (PDF/104KB)Finances

Sumitomo Dainippon Pharma Determines Issuance Conditions for Publicly Offered Hybrid Bonds (Subordinated Bonds)

IR Calendar

Oct. 28, 2020

2nd Quarter of FY2020 financial results announcement (3:30pm JST)

Related contents